Highly active antiretroviral therapy outcomes in a primary care clinic

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 15, Issue 2, 2003, Pages 231-237

  Rastegar, Darius A ^a,b   Fingerhood, M I ^a   Jasinski, D R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CONSULTATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; OUTCOMES RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE;

ADULT; AMBULATORY CARE FACILITIES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE;

EID: 0037394899     PISSN: 09540121     EISSN: None     Source Type: Journal    
DOI: 10.1080/0954012031000068371     Document Type: Article

References (23)

1. ALTICE, F.L. & FRIEDLAND, G.H. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503-505.
2. BANGSBERG, D.R., HECHT, F.M., CHARLEBOIS, E.D., ZOLOPA, A.R., HOLODNIY, M., SHEINER, L. ET AL. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14, 357-366.
3. BROSGART, C.L., MITCHELL, T.F., COLEMAN, R.L., DYNER, T., STEPHENSON, K.E. & ABRAMS, D.I. (1999). Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clinical Infectious Diseases, 28, 14-22.
4. CDC (1993). Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report, 41 (R-17).
5. DEEKS, S.G., HECHT, F.M., SWANSON, M., ELBEIK, T., LOFTUS, R., COHEN, P.T. & GRANT, R.M. (1999). HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS, 13, F35-F43.
6. DETELS, R., MUNOZ, A., MCFARLANE, G., KINGSLEY, L.A., MARGOLICK, J.B., GIORGI, J. ET AL. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Journal of the American Medical Association, 280, 1497-1503.
7. GULICK, R.M., MELLORS, J.W., HAVLIR, D., ERON, J.J., GONZALEZ, C., MCMAHON, D. ET AL. (1997). Treatment with indinavir, zidovudine, and lamuvidine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine, 337, 734-739.
8. GULICK, R.M., MELLORS, J.W., HAVLIR, D., ERON, J.J., MEMORY, A., CONDRA, J.H. ET AL. (2000). 3-year suppression of HIV viremia with indinavir, zidovudine, and lamuvidine. Annals of Internal Medicine, 133, 35-39.
9. HECHT, F.M., WILSON, I.B., WU, A.W., COOK, R.L. & TURNER, B.J. (1999). Optimizing care for persons with HIV infection. Annals of Internal Medicine, 131, 136-143.
10. KEMPF, D.J., RODE, R.A., XU, Y., SUN, E., HEATH-CHOZZI, M.E., VALDES, J. ET AL. (1998). The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS, 12, F9-F12.
11. KITHARA, M.M., KOEPSELL, T.D., DEYO, R.A., MAXWELL, C.L., DODGE, W.T. & WAGNER, E.H. (1996). Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. New England Journal of Medicine, 334, 701-706.
12. LANDON, B.E., WILSON, I.B., WEGNER, N.S., COHN, S.E., FICHTENBAUM, C.J., BOZZETTE, S.A. ET AL. (2002). Specialty training and specialization among physicians who treat HIV/AIDS in the United States. Journal of General Internal Medicine, 17, 12-22.
13. LUCAS, G.M., CHAISSON, R.E. & MOORE, R.D. (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-87.
14. LUCAS, G.M., CHEEVER, L.W., CHIASSON, R.E. & MOORE, R.D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of AIDS, 27, 251-259.
15. PALELLA, F.J., DELANEY, K.M., MOORMAN, A.C. ET AL. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-860.
16. PAREDES, R., MOCROFT, A., KIRK, O., LAZZARIN, A., BARTON, S.E., VAN LUNZEN, J. ET AL. (2000). Predictors of virologic success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Archives of Internal Medicine, 160, 1123-1132.
17. PATERSON, D.L., SWINDELLS, S., MOHR, J., BRESTER, M., VERGIS, E.N., SQUIER, C. ET AL. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
18. STASZEWSKI, S., MORALES-RAMIREZ, J., TASHIMA, K.T., RACHLIS, A., SKIEST, D., STANFORD, J. ET AL. (1999). Efavirenz plus zidovudine and lamuvidine, efavirenz plus indinavir, and indinavir plus zidovudine and lamuvidine in the treatment of HIV-1 infection in adults. New England Journal of Medicine, 341, 1865-1873.
19. THIEBAUT, R., MORLAT, P., JACQMIN-GADDA, H., NEAU, D., MERCIE, P., DABIS, F. ET AL. (2000). Clinical progression of HIV-1 infection according to the viral response during the first year of treatment. AIDS, 14, 971-978.
20. VALDEZ, H., LEDERMAN, M.M., WOOLLEY, I., WALKER, C.J., VERNON, L.T., HISE, A. & GRIPSHOVER, B.M. (1999). Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virologic outcome. Archives of Internal Medicine, 159, 1771-1776.
21. WILLIARD, C.L., LIJESTRAND, P., GOLDSCHMIDT, R.H. & GRUMBACH, K. (1999). Is experience with human immunodeficiency virus disease related to clinical practice? Archives of Family Medicine, 8, 502-508.
22. WOOD, E., YIP, B., HOGG, R.S., SHERLOCK, C.H., JAHNKE, N., HARRIGAN, R.P. ET AL. (2000). Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug therapy. AIDS, 14, 1955-1960.
23. ZUGER, A. & SHARP, V.L. (1997). 'HIV specialists': the time has come. Journal of the American Medical Association, 278, 1131-1132.